Moderna shares surge after positive cancer vaccine trial results
Moderna's stock surged on Wednesday following promising late-stage trial results for a cancer vaccine developed in collaboration with Merck. The news led to nearly $5 billion in paper losses for investors who had shorted the biotech company, according to Bloomberg. The significant market reaction highlights investor confidence in Moderna’s expanding pipeline beyond its well-known mRNA vaccines for infectious diseases into oncology treatments. This development marks a key milestone as it could position Moderna's cancer vaccine as an important therapeutic option if further trials continue to show positive results.
Topics: biotech cancer vaccine clinical trials stock price surge